While a study focused in cariporide, which abrogated the NHE-1 overexpression in the RV of rats with monocrotaline-induced PH [119], another study highlighted the role of rimeporide, which prevents functional, morphological, and biochemical deleterious effects of PAH in both the RV and lungs [120], thereby pointing at this drug as an efficient therapy to treat PAH. This evidence concerns the gene SLC9A1 and pulmonary arterial hypertension.